

1603

FAX COVER SHEET

OFFICIAL

FAX RECEIVED

No. of pages incl. this: 18

JUN 05 2002

Telefax no.: 703-872-9306

GROUP 1600

To: Examiner Ponnaluri

From: Jason Garbell

Date: June 4, 2002

Serial No: 09/426,038

OFFICIAL

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

Novozymes
North America, Inc.
Patents-US

500 Fifth Ave
Suite 1600
New York, NY 10110

Telephone:
(212)-840-0097
Telefax:
(212)-840-0221

email:
jgar@novozymes.com
internet:
www.novozymes.com

PATENT

Attorney Docket No.: 5579.210-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jesper Vind

Confirmation No: 1334

Serial No.: 09/426,038

Group Art Unit: 1627

Filed: October 25, 1999

Examiner: P. Ponnaluri

For: Methods Of Constructing And Screening A DNA Library Of Interest In Filamentous Fungal Cells

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed December 4, 2001.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from March 4, 2002 to June 4, 2002. The required fee for the extension is estimated to be \$920.

The fee for claims has been calculated as shown below:


Total: $26 - 24 = 2 \times 18 = \36 Independent: $2 - 3 = 0$

Total additional fee for claims required is \$36.

Please charge the required extension and claims fees, estimated to be \$956, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 4, 2002


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

6/11/2002 RHARMON 00000002 501701 09426038
File Ref: 00000008 DAW: 501701 09426038
FC:117 920.00 CH

FAX RECEIVED

JUN 05 2002

GROUP 1600
PATENT**OFFICIAL**

Attorney Docket No.: 5579.210-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jesper Vind

Confirmation No: 1334

Serial No.: 09/426,038

Group Art Unit: 1627

Filed: October 25, 1999

Examiner: P. Ponnaluri

For: Methods Of Constructing And Screening A DNA Library Of Interest In Filamentous Fungal Cells

CERTIFICATE OF FACSIMILE TRANSMISSIONCommissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner P. Ponnaluri, fax number (703) 872-9306.

Respectfully submitted,

Date: June 4, 2002



Jason Garbell
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 5579.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jesper Vind

Confirmation No: 1334

Serial No.: 09/426,038

Group Art Unit: 1627

Filed: October 25, 1999

Examiner: P. Ponnaluri

For: Methods Of Constructing And Screening A DNA Library Of Interest In Filamentous Fungal Cells

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed December 4, 2001, please amend the above-identified application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

IN THE CLAIMS:

Please cancel claim 12 without prejudice or disclaimer.

Please substitute the following amended claims for the pending claims having the same claim numbers:

1. (Twice Amended.) A method of screening a library of polynucleotide sequences of interest in filamentous fungal cells, wherein the method comprises:

(a) transforming the fungal cells with a population of DNA vectors, wherein each vector comprises:

- (i) a fungal selection marker polynucleotide sequence and a fungal replication initiating polynucleotide sequence, wherein the marker and the replication initiating sequence do not vary within the population; and wherein the replication initiating sequence is a nucleic acid sequence selected from the group consisting of: (1) a replication initiating sequence having at least 80% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:2, as determined using the GAP computer program with a GAP creation penalty of

06/11/2002 RHARMON 00000009 501701 09426038

01 FC:103

18.00 CH